ArticleAmerican journal of translational research2022
Correlation between pathological features and protein expressions of TfR1, VEGF and MMP-9 in patients with osteosarcoma.
Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 citations in OpenAlex.
- Beyond Iron: The Roles of CD71 in the Pathophysiology of Cancer-A Comprehensive Review.Journal of clinical medicine · 2025Review
- Potential of blood exosomal ENAH, SEPT9, EGF, MMP-9 and CXCL8 for the early screening of breast cancer.Oncology letters · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the pathological features of patients with osteosarcoma and the correlation of expressions of transferrin receptor 1 (TfR1), vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)-9 in tumor tissue with the pathological features.
methodsThe tumor tissue and paracancerous tissue samples from 31 patients with osteosarcoma were collected before treatment to measure the expressions of TfR1, VEGF and MMP-9. Kaplan-meier curve was used to analyze the relationship of TfR1, VEGF and MMP-9 with the survival time of patients. Log-rank test was used to test the difference, and Spearman test was used to test the correlation.
resultsAmong the 31 osteosarcoma samples, 23 (74.19%), 24 (77.42%) and 17 (54.84%) samples showed medium-high expressions of VEGF, TfR1 and MMP-9, respectively, which were significantly higher than those in the paracancerous samples (P<0.05). Furthemore, the medium-high expression rates of VEGF, TfR1 and MMP-9 were significantly different in patients with different Enneking stages, different histological differentiation degrees, and with or without distant metastasis. Besides, the expression of VEGF was also significantly different in different-size osteosarcoma samples (P<0.05). The survival time of patients with low expressions of TfR1, VEGF and MMP-9 was significantly longer than that of patients with medium-high expressions (P<0.05). Additionally, in osteosarcoma samples, significant positive correlations were shown between the expressions of TfR1 and VEGF, as well as between TfR1 and MMP-9 (P<0.05), but there was no significant correlation between VEGF and MMP-9 (P>0.05).
conclusionTfR1, VEGF and MMP-9 are abnormally expressed in osteosarcoma lesions, suggesting that they all play a role in the occurrence and development of osteosarcoma.
Indexed as
Identifiers
35958455PMC9360893W4291284993What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.